ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury

BACKGROUND: In contrast with various pre-clinical studies, recent clinical trials suggest that high dose erythropoietin (EPO) treatment following kidney transplantation does not improve short-term outcome and that it even increases the risk of thrombotic events. ARA290 is a non-erythropoietic EPO de...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: van Rijt, Willem G, Nieuwenhuijs-Moeke, Gertrude J, van Goor, Harry, Jespersen, Bente, Ottens, Petra J, Ploeg, Rutger J, Leuvenink, Henri GD
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2013
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3567997/
https://ncbi.nlm.nih.gov/pubmed/23302512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items